Physician profile
Prasad Chandra
NPI 1063468312
$2,907.51
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $907 · 2020: $573 · 2021: $1,250 · 2022: $117 · 2023: $61.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $61.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $61.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $756.27 | 2019-2021 | |
| Pfizer INC. | $348.03 | 2019-2021 | |
| Novo Nordisk INC | $238.10 | 2019-2022 | |
| Abbott Laboratories | $182.13 | 2021-2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Abbvie INC. | $172.62 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.91 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $137.43 | 2020-2021 | |
| Lilly USA, LLC | $127.19 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $116.27 | 2019-2021 | |
| Amgen INC. | $101.12 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.50 | 2019-2021 | |
| Amarin Pharma, INC. | $73.28 | 2020-2021 | |
| Allergan, INC. | $66.76 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $54.56 | 2019-2020 | |
| Esperion Therapeutics, INC. | $42.93 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $41.29 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.10 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.19 | 2020 | |
| Merck Sharp & Dohme LLC | $29.78 | 2020-2021 | |
| Shire North American Group INC | $26.62 | 2019 | |
| Astellas Pharma US INC | $19.94 | 2019 | |
| Sanofi-Aventis U.S. LLC | $19.57 | 2021 | |
| Dexcom, INC. | $17.68 | 2021 | |
| Si-Bone, INC. | $14.99 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $12.15 | 2021 | |
| Horizon Therapeutics Plc | $12.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prasad Chandra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.